Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration

Andrew S. Mikhail, Ivane Bakhutashvili, W. Pritchard, Dieter Haemmerich, Rochel Hecht, Reza Seifabadi, Matthew F. Starost, Rachel Ashe, Keith T. Schmidt, William D. Figg, Bradford J. Wood, John W. Karanian, Michal Mauda‐HavakukFrontiers in Pharmacology 2026 · DOI

Abstract

Intravenous (IV) and intra-arterial (IA) administration of lyso-thermosensitive liposomal doxorubicin (LTLD), combined with localized rectal hyperthermia, were evaluated in a swine model. Both routes produced similar, significant increases in rectal doxorubicin concentrations compared to normothermic controls. These findings demonstrate the feasibility of integrating thermosensitive nanomedicine with localized heating and suggest that standard IV delivery may be as effective as more invasive IA catheterization for targeted rectal therapy.

Introduction

The treatment of rectal cancer requires a delicate balance between therapeutic efficacy and systemic toxicity. Doxorubicin is a potent chemotherapeutic agent, but its clinical utility is often limited by severe side effects, most notably irreversible cardiotoxicity. Furthermore, achieving therapeutic drug concentrations within deep rectal tumor tissues is challenging due to physiological barriers such as high interstitial fluid pressure and irregular vascularization.

To address these challenges, researchers have developed lyso-thermosensitive liposomal doxorubicin (LTLD). This "smart" delivery system encapsulates doxorubicin within lipid vesicles that remain stable at normal body temperature but rapidly release their payload when exposed to mild hyperthermia (39°C–42°C). While LTLD has shown promise in other malignancies, its specific application for rectal delivery—and the optimal route of administration (IV vs. IA)—remains a critical area of investigation.

Methods

The study utilized a dual approach involving computational modeling and an in vivo swine model, chosen for its anatomical similarity to humans.

Hardware and Hyperthermia Induction

A custom rectal heating device was engineered to provide precise, localized hyperthermia. The device consists of a heat-conductive copper cylinder through which 44°C water is circulated from a temperature-controlled bath. This setup ensures a homogeneous temperature profile at the rectal wall.

Design and fabrication of the custom rectal heating device.

Experimental Design

Eight healthy female Yorkshire swine were divided into four experimental groups (n=2 per group) to compare delivery routes and the impact of heat:

  1. IV LTLD (Normothermic): Standard intravenous injection without local heating.
  2. IA Free Doxorubicin + Heat: Direct intra-arterial injection of non-encapsulated doxorubicin with local rectal heating.
  3. IV LTLD + Heat: Standard intravenous injection with localized rectal hyperthermia.
  4. IA LTLD + Heat: Direct intra-arterial injection of LTLD with localized rectal hyperthermia.

Drug concentrations were quantified using liquid chromatography-mass spectrometry (LC/MS) in rectal tissue, heart, and fat. Fluorescence microscopy was employed to visualize the depth of drug penetration within the tissue layers.

Results

Enhanced Local Drug Delivery

The application of localized hyperthermia acted as a "master switch" for drug release. Both IV and IA LTLD with heat resulted in massive increases in rectal tissue concentrations: 7.45 ± 6.18 µg/g and 8.41 ± 5.15 µg/g, respectively. In contrast, the normothermic IV group reached only 0.49 ± 0.16 µg/g, representing a more than 15-fold increase when heat was applied.

Notably, LTLD significantly outperformed "naked" doxorubicin. Even with direct IA injection and heat, free doxorubicin only achieved a tissue concentration of 0.67 ± 0.46 µg/g, highlighting the superior targeting capability of the liposomal formulation.

Systemic Safety and Tissue Penetration

Despite the high local concentrations, doxorubicin levels in the heart remained consistently low across all groups. This confirms that the liposomes effectively shield systemic tissues from the drug until the thermal trigger is encountered. Fluorescence imaging further revealed that the drug successfully penetrated the full thickness of the rectal wall, reaching the muscular layers essential for treating invasive tumors.

Discussion

A key insight from this study is that the route of administration (IV vs. IA) had a negligible impact on local drug accumulation when paired with hyperthermia. While IA delivery is often preferred for "first-pass" exposure in local therapies, the relatively long circulation time of LTLD allows IV-delivered liposomes to repeatedly pass through the heated target zone, eventually matching the efficiency of direct arterial injection.

Limitations and Future Directions

While promising, several factors must be addressed before clinical translation. This study used healthy swine; the chaotic vasculature and pressure gradients of actual tumors may alter drug distribution. The small sample size (n=2 per group) limits statistical power, although the observed trends were consistent. Future research should include survival studies to evaluate long-term tissue retention and tumor regression. Additionally, clinical implementation will require a more flexible heating device design with integrated safety sensors for human use.

Conclusion

This study demonstrates that combining LTLD with localized hyperthermia can achieve high, targeted drug concentrations in rectal tissue while maintaining systemic safety. The finding that IV administration is nearly as effective as IA delivery suggests a simpler, less invasive clinical path for enhancing chemotherapy in rectal cancer patients.

Summary updated

Abstract

Intravenous and intra-arterial LTLD combined with localized rectal hyperthermia produced similar increases in rectal doxorubicin concentrations in a swine model. These findings support the feasibility of integrating thermosensitive liposomal drug delivery with localized rectal hyperthermia and intra-arterial catheter-based delivery.
BibTeX
@inproceedings{mikhail2026hyperthermia,
  author = {Andrew S. Mikhail and Ivane Bakhutashvili and W. Pritchard and Dieter Haemmerich and Rochel Hecht and Reza Seifabadi and Matthew F. Starost and Rachel Ashe and Keith T. Schmidt and William D. Figg and Bradford J. Wood and John W. Karanian and Michal Mauda‐Havakuk},
  title = {{Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration}},
  booktitle = {Frontiers in Pharmacology},
  year = {2026},
  doi = {10.3389/fphar.2026.1760944},
}
Figure